The dual NDA acceptances de-risk the near-term regulatory path and create a clear catalyst calendar: relutrigine PDUFA Sep 27, 2026, ulixacaltamide PDUFA Jan 29, 2027, plus POWER1 readout in Q2 2026 and EMERALD in Q4 2026. The $1.4B cash runway into 2028 eliminates financing risk. Traders should watch for POWER1 topline results (likely within weeks) as the next major catalyst, a positive readout would validate vormatrigine's broad epilepsy potential and likely drive further upside.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-050 Fresh report · subscribers
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $333.28entry
- T+1 · 6mo ago −0.98%α −1.81% · $330.02
- T+5 · 6mo ago +4.07%α +2.56% · $346.84
- T+20 · 6mo ago −16.31%α −19.44% · $278.93
- T+60 · 4mo ago −8.33%α −12.17% · $305.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline is the FDA acceptance of NDAs for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (priority review, PDUFA Sep 27, 2026), positioning for two U.S. launches within eight months. The company also reported a 77% placebo-adjusted seizure reduction for elsunersen in early-seizure-onset SCN2A-DEE and maintains a $1.4B cash runway into 2028, funding multiple upcoming catalysts including POWER1 (FOS) topline in Q2 2026 and EMERALD (broad DEEs) in Q4 2026.
Key Financial Metrics
Key Facts
- FDA accepted NDA for ulixacaltamide in Essential Tremor with PDUFA Jan 29, 2027
- FDA accepted relutrigine NDA with priority review for SCN2A/SCN8A DEEs, PDUFA Sep 27, 2026
- Elsunersen showed 77% placebo-adjusted seizure reduction in EMBRAVE Part A (p=0.015)
- Cash and investments $1.4B as of March 31, 2026, up from $926.1M at Dec 31, 2025
- Net loss $92.6M in Q1 2026 vs $69.3M in Q1 2025, driven by increased R&D and G&A spend
- EPS of -$3.20 beat consensus of -$3.68 (2.7% beat)
- POWER1 (vormatrigine) topline results expected Q2 2026; EMERALD (relutrigine) topline Q4 2026
- Commercial organization build underway for both ulixacaltamide and relutrigine launches
Financial Impact
EPS beat of $0.48 vs consensus; cash position increased by $473.9M from follow-on offering
Risk Factors
- Regulatory risk: FDA could issue CRLs for either NDA despite Breakthrough Therapy designations
- Clinical risk: POWER1 (vormatrigine) or EMERALD (relutrigine) could miss endpoints
- Commercial execution risk: launching two drugs simultaneously in 2027 requires significant infrastructure
- Dilution risk: company may need additional capital if launches are delayed or cash burn accelerates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289917 |
Track record
16 reports on PRAX
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Viewing Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers